This is a very positive development, if it holds up: A new medicine for schizophrenia that helps the negative symptoms…often the toughest to deal with in recovery.
RG1678, a so-called glycine reuptake inhibitor, was effective in reducing the “negative symptoms” of schizophrenia, Roche said Dec. 6. These include a loss of motivation and interest in social activities, isolation and difficulty finding pleasure in everyday life, the company said. Current treatments for the disease mostly address the positive symptoms for the disease, which include hallucinations and delusions, Roche said.
The mental disorder affects about 24 million people worldwide and is usually diagnosed in people aged between 15 and 35 years old, Roche said.